As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Adlai Nortye Ltd. The largest reported stake is ANL Talent Limited's, at 7.75%. 8 filings are on record since January 16, 2026 (Schedule 13G, January 16, 2026).
Sell to companies like Adlai Nortye Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 3,978,229 · Sole dispositive: 0 · Shared dispositive: 3,978,229 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 9,638,193 · Sole dispositive: 0 · Shared dispositive: 9,638,193 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Cormorant Asset Management, LP · Percent: 5.19% · SCHEDULE 13G
- · Reporting person: Jin Yin (Bvi) Limited · Sole voting: 4,561,077 · Shared voting: 0 · Sole dispositive: 4,561,077 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-14
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 6.1% · SCHEDULE 13G
Adlai Nortye Ltd. has 8 Schedule 13D or 13G filings on record since 2026-01-16. 2 holders' latest filing reports 5% or more of class a ordinary shares, par value us$0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ANL Talent Limited | 7.75% | 9,300,000 | SCHEDULE 13G, 2026-01-16 | 2025-12-31 |
| Cormorant Asset Management, LP | 6.77% | 3,978,229 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Venrock Healthcare Capital Partners III, L.P. | 4.4% | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Jin Yin (Bvi) Limited | 2.9% | 4,561,077 | SCHEDULE 13G/A, 2026-05-14 | 2023-12-31 |
| Unique Mark Ventures Ltd | 0% | 0 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-09 |
Holding shares or following this stake? See who's behind Adlai Nortye Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Adlai Nortye Ltd. and the records around it.
Adlai Nortye Ltd. elsewhere on the record
Companies that share a holder
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), BioAge Labs, Inc. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Adlai Nortye Ltd.
Get an email when Adlai Nortye Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adlai Nortye Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Adlai Nortye Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adlai Nortye Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 0 | 3,978,229 | 0 | 3,978,229 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 3,978,229 | 0 | 3,978,229 | SCHEDULE 13G/A, 2026-08-14 |
| Venrock Healthcare Capital Partners III, L.P. | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| VHCP Co-Investment Holdings III, LLC | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| Venrock Healthcare Capital Partners EG, L.P. | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| VHCP Management III, LLC | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| VHCP Management EG, LLC | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| Nimish Shah | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| Bong Y. Koh | 0 | 9,638,193 | 0 | 9,638,193 | SCHEDULE 13G/A, 2026-08-14 |
| Jin Yin (Bvi) Limited | 4,561,077 | 0 | 4,561,077 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Shanghai Gaopei Duwei Biotechnology Co., Ltd. | 4,561,077 | 0 | 4,561,077 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Hangzhou Jingyin Investment Partnership (Limited Partnership) | 4,561,077 | 0 | 4,561,077 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Hangzhou Jingfeng Investment Management Company | 4,561,077 | 0 | 4,561,077 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Shijun Feng | 4,561,077 | 0 | 4,561,077 | 0 | SCHEDULE 13G/A, 2026-05-14 |
The latest filing identifies Adlai Nortye Ltd. by CUSIP 00704R109 and gives its principal executive office as c/o PO Box 309, Ugland House, Grand Cayman (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of Class A ordinary shares of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14
See Item 11 of each cover page. The calculation is based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.Jin Yin (Bvi) Limited, SCHEDULE 13G/A, 2026-05-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-16 | ANL Talent Limited | 7.75% | SCHEDULE 13G |
| 2026-01-20 | Unique Mark Ventures Ltd | 6.14% | SCHEDULE 13G |
| 2026-02-09 | Unique Mark Ventures Ltd | 0% | SCHEDULE 13G/A |
| 2026-02-11 | Venrock Healthcare Capital Partners III, L.P. | 6.1% | SCHEDULE 13G |
| 2026-05-14 | Jin Yin (Bvi) Limited | 2.9% | SCHEDULE 13G/A |
| 2026-05-15 | Cormorant Asset Management, LP | 5.19% | SCHEDULE 13G |
| 2026-08-14 | Cormorant Asset Management, LP | 6.77% | SCHEDULE 13G/A |
| 2026-08-14 | Venrock Healthcare Capital Partners III, L.P. | 4.4% | SCHEDULE 13G/A |
Questions about who owns Adlai Nortye Ltd.
Who owns Adlai Nortye Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Adlai Nortye Ltd.: ANL Talent Limited (7.75%, Schedule 13G, filed 2026-01-16) and Cormorant Asset Management, LP (6.77%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Adlai Nortye Ltd.?
By the share each holder's latest filing reports, the largest holders of Adlai Nortye Ltd. on this page are ANL Talent Limited (7.75%) and Cormorant Asset Management, LP (6.77%).
When did ANL Talent Limited buy into Adlai Nortye Ltd.?
The filings give report dates, not purchase dates. The earliest filing from ANL Talent Limited on this page is the Schedule 13G, filed 2026-01-16, reporting 7.75%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Adlai Nortye Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.